What this covers

Patrick interviews D.A. Wallach, a life sciences venture investor, in a conversation recorded as the coronavirus pandemic was taking hold. It runs between the mechanics of healthcare venture and the biology underneath it. On the investing side, Wallach explains how big pharma gave up internal early-stage research and now faces a patent cliff. He describes how firms in Boston and San Francisco license university IP, install experienced biopharma executives as founders, and often own 80 or 90 percent of a company from day one. His starting rule is to identify the exits first, since getting into venture deals is far easier than getting out.

The personal thread is his wife's MLH1 mutation, which gives her an 80 percent-plus chance of cancer. Through IVF and embryo sequencing, their daughter was spared it. That anchors a tour of gene therapy, the base editing approach of Beam Therapeutics, and why correcting a few embryonic cells is more tractable than editing trillions in an adult. He argues the first uses should target unambiguous suffering, not embryo selection. He also covers the gut microbiome as a new biological frontier, while warning the science may be early, and Google's Project Baseline, which measures what healthy biomarkers look like.

The contentious stretches concern costs and harms. Wallach works through the layers of drug pricing, the claim that hospitals act as local monopolies, and why cell therapies can cost $200,000 to $300,000 per dose to make. He also covers the missing incentive for new antibiotics, and the arithmetic of screening: a 99 percent specific test still yields roughly 3 million false positives across 300 million people. He rejects medical nihilism but concedes that over-treatment, such as back and prostate surgery, is real.

Sharpest takeaway

D.A. Wallach argues that healthcare is moving from symptom control (medicine 1.0) to prevention and cure (medicine 2.0), and that venture investors should work backward from big pharma's structural need to buy replacement products, since exits drive returns.

  • Big pharma divested internal early-stage R&D and now acts as a forced buyer of startups spending $20-30 billion a year
  • Drug price increases are largely a product of list-price inflation and rebate mechanics, with net prices rising far less
  • Diagnostic testing and over-treatment create false-positive harms that must be weighed alongside continuous monitoring

The argument · threads2 threads · 65 claims
0.71

The shifting balance between product and distribution is a cross-industry pattern, seen in uneven health tool access.

2 pointscentrality 4/5
  • The swinging pendulum between product and distribution, and between fragmentation and concentration of distribution and suppliers, may be the most interesting pattern across every industry.

    “You could probably say that that pendulum of product and distribution swings in every industry”

  • Patrick framed the existence of wearable glucose monitors and similar tools among health-forward investors as an instance of William Gibson's idea that the future is already here but unevenly distributed.

    “It's an interesting place to apply the William Gibson idea that the future is here, just not evenly distributed.”

0.15

The episode's early-coronavirus recording is context, not its primary focus.

1 pointcentrality 1/5
  • The episode was recorded in the early days of the coronavirus outbreak, and while it is touched upon, it is not the primary focus.

    “This was recorded in the very early days of the coronavirus outbreak.”